Clinical Research Directory
Browse clinical research sites, groups, and studies.
99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors
Sponsor: Nanjing First Hospital, Nanjing Medical University
Summary
At present, radiopharmaceuticals targeting FAP have been developed for the diagnosis and treatment of various tumors. Considering the problems of fast tumor tissue clearance and short retention time in small molecule FAP inhibitors based on quinoline rings, this project optimized their ligands and developed a new FAP targeted technetium labeled molecular imaging probe for SPECT/CT imaging research to evaluate its safety in clinical application and its effectiveness in tumor diagnosis.
Official title: Clinical Application of a Novel 99mTc Labeled Fibroblast Activating Protein (FAP) Targeted Molecular Probe in Early Diagnosis of Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
20
Start Date
2024-06-01
Completion Date
2026-05-31
Last Updated
2025-03-11
Healthy Volunteers
No
Interventions
SPECT-CT imaging
The subjects were intravenously injected with 99mTc labeled FAPI imaging agent, and drank 300-500ml of water after administration. SPECT-CT imaging was performed 60 minutes later
Locations (1)
Nanjing First Hospital
Nanjing, Jiangsu, China